End-of-day quote
Other stock markets
|
||
- | - |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 492M 0 38.65B |
---|---|---|---|---|---|
Net income 2024 * | -66M - -5.19B | Net income 2025 * | -78M - -6.13B | EV / Sales 2024 * | - |
Net cash position 2024 * | 327M 0 25.71B | Net cash position 2025 * | 501M 0 39.39B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.53
x | P/E ratio 2025 * |
-10.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |